ClinicalTrials.gg
CompletedNCT00830050Updated Mar 14, 2011

Brain Imaging To Examine The Effect Of Naproxen In Hand Osteoarthritis Patients

An Early Phase 1 interventional study of Naproxen and Placebo in Osteoarthritis, sponsored by Pfizer. Completed at 1 site in United Kingdom. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-03-14.

Sponsored by Pfizer · Early Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 14 studies testing naproxen in Osteoarthritis — none open to participants now, 1 under way, none of them phase 3. Naproxen · Osteoarthritis.

Enrollment
12th of 14
24 · median 103
Started
2010
with 1 other
Phase 1
5 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
6 of 14
Pfizer

Among the 14 studies testing naproxen in Osteoarthritis, this one is the 12th largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 1, and was the 9th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 14 studies testing naproxen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 50 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing naproxen in Osteoarthritis as a file.
02

Study summary

The study hypothesis is that the relief of pain in patients with osteoarthritis in the hand can be detected by a form of brain scanning that detects which parts of the brain are activated when pain is felt.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • fMRI functional magnetic resonance imaging Pain
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Right-handed, female, any race, 50-80 years
  • Clinical diagnosis of osteoarthritis of the hand
  • Estimated pain in this joint of at least 5 on a scale of 0 to 10

Exclusion criteria

Exclusion Criteria:

  • Any patient who smokes more than 5 cigarettes per day
  • Patients receiving some anti-depressant drugs unless the dose is stable
  • Patients unable to be admitted or lie still in an MRI scanner
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Naproxen

  • Placebo comparator
    Arm 2

    Drug: Placebo

Interventions

  • 500 mg BID 7 days

  • DrugPlacebo

    BID 7 days

06

What researchers measure

Primary outcomes

  1. Changes in voxel-wise Blood Oxygen Level Dependent (BOLD) signal throughout the brain and changes in pre-defined brain regions of interest.

    Time frame: 22 days

Secondary outcomes

  1. Whole brain resting-state distribution of Cerebral Blood Flow

    Time frame: 22 days

  2. Psychometric measures of pain, namely Daily Pain Diaries and Present Pain Intensity

    Time frame: 22 days

  3. Pain induced by a grip task measured with a Visual Analogue Scale (VAS), the Short-Form McGill Pain Questionnaire and patient-rated wrist/hand evaluation (PRWHE)

    Time frame: 22 days

07

Study locations

1 site
  • Pfizer Investigational Site
    Denmark Hill, London SE5 8AF, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2009
First posted
Jan 27, 2009
Start
Jul 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Last update
Mar 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00830050
Lead sponsor
Pfizer
First posted
Jan 27, 2009
Start date
Jul 2010
Primary completion
Dec 2010
Completion
Dec 2010
Last update
Mar 14, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion